The Jefferies Group has reiterated its "buy" rating of AmSurg stock, according to a Dakota Financial News report.
Cantor Fitzgerald, Goldman Sachs and Zacks also have a "buy" rating on the stock, according to the report.
AmSurg has a 52-week low of $44.61 and 52-week high of $70.53.